Latest News and Press Releases

Want to stay updated on the latest news?

Sign into Reader Account Create Reader Account

April 26, 2019 12:59 ET | Source: Innovate Biopharmaceuticals, Inc

Innovate Biopharmaceuticals First Quarter 2019 Financial Results and Operational Progress Updates - Webcast Details

RALEIGH, N.C., April 26, 2019 (GLOBE NEWSWIRE) -- Innovate Biopharmaceuticals, Inc. (“Innovate”) (Nasdaq: INNT), a clinical stage biotechnology company focused on developing novel autoimmune and...
April 11, 2019 09:45 ET | Source: Innovate Biopharmaceuticals, Inc

Innovate Biopharmaceuticals Presents Oral Poster at European Association for the Study of the Liver (EASL) Demonstrating Positive Effect of Larazotide on Reduced Intestinal Permeability in a NASH Preclinical Study

Selected for oral poster tour by the scientific committee in the gut microbiota section at the International Liver CongressTM 2019 of EASL Data presented as a poster showing significant effect on gut...
April 02, 2019 07:00 ET | Source: Innovate Biopharmaceuticals, Inc

Innovate Biopharmaceuticals to Announce First Quarter 2019 Financial Results and to Provide Operational Progress Updates on April 29, 2019

Innovate plans to provide an operational progress update, including regarding its first phase 3 celiac disease clinical trial Topline NASH preclinical data expected to be released at the Digestive...
March 26, 2019 09:32 ET | Source: Innovate Biopharmaceuticals, Inc

Innovate Biopharmaceuticals Announces Collaboration with Institut Gustave Roussy to Study Regulation of Intestinal Permeability and the Gut Microbiota using Larazotide in Immuno-oncology Checkpoint Inhibitor Failure Pre-Clinical Models

RALEIGH, N.C., March 26, 2019 (GLOBE NEWSWIRE) -- Innovate Biopharmaceuticals Inc. (Nasdaq: INNT), a clinical stage biotechnology company focused on developing novel therapeutics for autoimmune and...
March 19, 2019 07:45 ET | Source: Innovate Biopharmaceuticals, Inc

Innovate Biopharmaceuticals Reports Financing to Initiate the First Phase 3 Clinical Trial in Celiac Disease, Fiscal Year 2018 Earnings and Key Corporate Highlights

Innovate closes an equity financing with gross proceeds of $9.7 million Continued launch activities for start of the first Phase 3 celiac disease trial, expected to start Q2 2019 Continued research...
March 18, 2019 19:30 ET | Source: Innovate Biopharmaceuticals, Inc

Innovate Biopharmaceuticals to Discuss Fourth Quarter and Full Year 2018 Financial Results and to Provide Corporate and Operational Progress Updates on March 19, 2019

RALEIGH, N.C., March 18, 2019 (GLOBE NEWSWIRE) -- Innovate Biopharmaceuticals, Inc. (“Innovate”) (Nasdaq: INNT), a clinical stage biotechnology company focused on developing novel autoimmune and...
March 18, 2019 08:51 ET | Source: Innovate Biopharmaceuticals, Inc

Innovate Biopharmaceuticals Announces Entry Into Securities Purchase Agreement to Fund Initiation of the First Phase 3 Celiac Disease Clinical Trial

RALEIGH, N.C., March 18, 2019 (GLOBE NEWSWIRE) -- Innovate Biopharmaceuticals, Inc. (“Innovate” or the “Company”) (Nasdaq: INNT), a clinical stage biotechnology company focused on developing novel...
March 13, 2019 19:00 ET | Source: Innovate Biopharmaceuticals, Inc

Innovate Biopharmaceuticals to Announce Fourth Quarter and Full Year 2018 Financial Results and to Provide Corporate and Operational Progress Updates on March 18, 2019

RALEIGH, N.C., March 13, 2019 (GLOBE NEWSWIRE) -- Innovate Biopharmaceuticals, Inc. (“Innovate”) (Nasdaq: INNT), a clinical stage biotechnology company focused on developing novel autoimmune and...
March 06, 2019 09:00 ET | Source: Innovate Biopharmaceuticals, Inc

Innovate Biopharmaceuticals Announces Presentation at Cowen’s 39th Annual Health Care Conference in Boston

RALEIGH, N.C., March 06, 2019 (GLOBE NEWSWIRE) -- Innovate Biopharmaceuticals, Inc. (Nasdaq: INNT), a clinical stage biotechnology company focused on developing novel autoimmune and inflammation...
March 01, 2019 17:33 ET | Source: Innovate Biopharmaceuticals, Inc

Innovate Biopharmaceuticals to Announce Fourth Quarter and Full Year 2018 Financial Results and to Provide Corporate and Operational Progress Updates on March 14, 2019

RALEIGH, N.C., March 01, 2019 (GLOBE NEWSWIRE) -- Innovate Biopharmaceuticals, Inc. (“Innovate”) (Nasdaq: INNT), a clinical stage biotechnology company focused on developing novel autoimmune and...